tag :: Neoplasms humans

bookmarks (hide)
display
all
bookmarks only
bookmarks per page
5
10
20
50
100
sort by
added at
title
RSS
BibTeX
XML

No matching posts.

⟨⟨
⟨
⟩
⟩⟩

publications (hide)124
display
all
publications only
publications per page
5
10
20
50
100
sort by
added at
title
author
publication date
entry type
help for advanced sorting...
RSS
BibTeX
RDF
more...

1Precision of incidence predictions based on Poisson distributed observations.
T. Hakulinen, and T. Dyba. Statistics in medicine, 13 (15): 1513-23 (August 1994)2440.
2 years ago by @jepcastel
show all tags
Adult
AgeFactors
ConfidenceIntervals
Female
Forecasting
Humans
Incidence
LinearModels
Male
MiddleAged
Neoplasms
Neoplasms:epidemiology
Nonparametric
PoissonDistribution
Statistics
Sweden
Sweden:epidemiology
AdultAgeFactorsConfidenceIntervalsFemaleForecastingHumansIncidenceLinearModelsMaleMiddleAgedNeoplasmsNeoplasms:epidemiologyNonparametricPoissonDistributionStatisticsSwedenSweden:epidemiology
(0)
copydeleteadd this publication to your clipboard
1An electronic application for rapidly calculating Charlson comorbidity score.
W. Hall, R. Ramachandran, S. Narayan, A. Jani, and S. Vijayakumar. BMC cancer, (December 2004)4050<m:linebreak></m:linebreak>Comorbiditat.
2 years ago by @jepcastel
show all tags
Aged
Comorbidity
Humans
MathematicalComputing
Neoplasms
Neoplasms:mortality
OutcomeAssessment(HealthCare)
OutcomeAssessment(HealthCare):methods
ReproducibilityofResults
Risk
TreatmentOutcome
AgedComorbidityHumansMathematicalComputingNeoplasmsNeoplasms:mortalityOutcomeAssessment(HealthCare)OutcomeAssessment(HealthCare):methodsReproducibilityofResultsRiskTreatmentOutcome
(0)
copydeleteadd this publication to your clipboard
1Mortality from tobacco in developed countries: indirect estimation from national vital statistics.
R. Peto, A. Lopez, J. Boreham, M. Thun, and C. Heath. Lancet, 339 (8804): 1268-78 (May 1992)4321<m:linebreak></m:linebreak>LR: 20041117; PUBM: Print; JID: 2985213R; CIN: Lancet. 1992 Jul 11;340(8811):121. PMID: 1351994; CIN: Lancet. 1992 Jun 13;339(8807):1484. PMID: 1351160; CIN: Lancet. 1992 Jun 13;339(8807):1484. PMID: 1351161; CIN: Lancet. 1992 Sep 12;340(8820):666. PMID: 1355221; CIN: Lancet. 1992 Sep 12;340(8820):666-8. PMID: 1355222; ppublish;<m:linebreak></m:linebreak>Risc atribuïble.
2 years ago by @jepcastel
show all tags
80andover
Adult
Aged
CardiovascularDiseases
CardiovascularDiseases:mortality
DataInterpretation
Europe
Europe:epidemiology
Female
Humans
LifeExpectancy
LungDiseases
LungDiseases:mortality
Male
MiddleAged
Neoplasms
Neoplasms:mortality
PopulationSurveillance
ProspectiveStudies
Risk
Smoking
Smoking:adverseeffects
Smoking:mortality
Statistical
UnitedStates
UnitedStates:epidemiology
80andoverAdultAgedCardiovascularDiseasesCardiovascularDiseases:mortalityDataInterpretationEuropeEurope:epidemiologyFemaleHumansLifeExpectancyLungDiseasesLungDiseases:mortalityMaleMiddleAgedNeoplasmsNeoplasms:mortalityPopulationSurveillanceProspectiveStudiesRiskSmokingSmoking:adverseeffectsSmoking:mortalityStatisticalUnitedStatesUnitedStates:epidemiology
(0)
copydeleteadd this publication to your clipboard
1A unified approach to the analysis of case-distribution (case-only) studies.
S. Greenland. Statistics in medicine, 18 (1): 1-15 (January 1999)2701<m:linebreak></m:linebreak>Dissenys híbrids.
2 years ago by @jepcastel
show all tags
Case-ControlStudies
Child
Cross-OverStudies
ElectromagneticFields
ElectromagneticFields:adverseeffects
Humans
LikelihoodFunctions
Neoplasms
Neoplasms:epidemiology
Neoplasms:etiology
RegressionAnalysis
Case-ControlStudiesChildCross-OverStudiesElectromagneticFieldsElectromagneticFields:adverseeffectsHumansLikelihoodFunctionsNeoplasmsNeoplasms:epidemiologyNeoplasms:etiologyRegressionAnalysis
(0)
copydeleteadd this publication to your clipboard
1On the measurement of susceptibility in epidemiologic studies.
M. Khoury, W. Flanders, S. Greenland, and M. Adams. American journal of epidemiology, 129 (1): 183-90 (January 1989)3174<m:linebreak></m:linebreak>Risc atribuïble.
2 years ago by @jepcastel
show all tags
Abnormalities
ChronicDisease
DiseaseSusceptibility
Drug-Induced
Drug-Induced:epidemiology
EpidemiologicMethods
Humans
Neoplasms
Neoplasms:epidemiology
Neoplasms:etiology
RiskFactors
Smoking
Smoking:adverseeffects
AbnormalitiesChronicDiseaseDiseaseSusceptibilityDrug-InducedDrug-Induced:epidemiologyEpidemiologicMethodsHumansNeoplasmsNeoplasms:epidemiologyNeoplasms:etiologyRiskFactorsSmokingSmoking:adverseeffects
(0)
copydeleteadd this publication to your clipboard
1The statistics of phase 0 trials.
L. Rubinstein, S. Steinberg, S. Kummar, R. Kinders, R. Parchment, A. Murgo, J. Tomaszewski, and J. Doroshow. Statistics in medicine, 29 (10): 1072-6 (May 2010)6503<m:linebreak></m:linebreak>JID: 8215016; 0 (Antineoplastic Agents); 0 (Drugs, Investigational); ppublish;<m:linebreak></m:linebreak>Disseny; Fase 0.
2 years ago by @jepcastel
show all tags
AntineoplasticAgents
AntineoplasticAgents:administration&dosage
AntineoplasticAgents:pharmacokinetics
ClinicalTrialsasTopic
ClinicalTrialsasTopic:methods
DataInterpretation
Drugs
Humans
Investigational
Investigational:pharmacokinetics
Investigational:pharmacology
Neoplasms
Neoplasms:drugtherapy
Neoplasms:metabolism
Pharmacokinetics
Statistical
AntineoplasticAgentsAntineoplasticAgents:administration&dosageAntineoplasticAgents:pharmacokineticsClinicalTrialsasTopicClinicalTrialsasTopic:methodsDataInterpretationDrugsHumansInvestigationalInvestigational:pharmacokineticsInvestigational:pharmacologyNeoplasmsNeoplasms:drugtherapyNeoplasms:metabolismPharmacokineticsStatistical
(0)
copydeleteadd this publication to your clipboard
1Progression-free survival remains debatable endpoint in cancer trials.
R. Tuma. Journal of the National Cancer Institute, 101 (21): 1439-41 (November 2009)5434<m:linebreak></m:linebreak>JID: 7503089; 0 (Antineoplastic Agents); 2009/10/14 aheadofprint; ppublish;<m:linebreak></m:linebreak>Anàlisi de supervivència.
2 years ago by @jepcastel
show all tags
AntineoplasticAgents
AntineoplasticAgents:therapeuticuse
ClinicalTrialsasTopic
DataInterpretation
Disease-FreeSurvival
Humans
KidneyNeoplasms
KidneyNeoplasms:drugtherapy
Neoplasms
Neoplasms:drugtherapy
Statistical
TreatmentOutcome
AntineoplasticAgentsAntineoplasticAgents:therapeuticuseClinicalTrialsasTopicDataInterpretationDisease-FreeSurvivalHumansKidneyNeoplasmsKidneyNeoplasms:drugtherapyNeoplasmsNeoplasms:drugtherapyStatisticalTreatmentOutcome
(0)
copydeleteadd this publication to your clipboard
1Evolution of cancer survival analysis.
S. Maetani, and J. Gamel. Surgical oncology, 19 (2): 49-51; discussion 61 (June 2010)6176<m:linebreak></m:linebreak>JID: 9208188; 2010/03/04 received; 2010/03/12 accepted; 2010/04/07 aheadofprint; ppublish;<m:linebreak></m:linebreak>Anàlisi de supervivència.
2 years ago by @jepcastel
show all tags
DiseaseProgression
Humans
Japan
Japan:epidemiology
Models
Neoplasms
Neoplasms:epidemiology
Neoplasms:mortality
ProportionalHazardsModels
RegressionAnalysis
Statistical
SurvivalAnalysis
UnitedStates
UnitedStates:epidemiology
DiseaseProgressionHumansJapanJapan:epidemiologyModelsNeoplasmsNeoplasms:epidemiologyNeoplasms:mortalityProportionalHazardsModelsRegressionAnalysisStatisticalSurvivalAnalysisUnitedStatesUnitedStates:epidemiology
(0)
copydeleteadd this publication to your clipboard
1How to improve reliability and efficiency of research about molecular markers: roles of phases, guidelines, and study design.
D. Ransohoff. Journal of clinical epidemiology, 60 (12): 1205-19 (December 2007)JID: 8801383; 0 (Genetic Markers); 0 (Tumor Markers, Biological); RF: 103; 2006/09/15 received; 2007/04/01 revised; 2007/04/12 accepted; 2007/09/24 aheadofprint; ppublish;;<m:linebreak></m:linebreak> <m:linebreak></m:linebreak>Disseny; Proves diagnòstiques; Models predictius.
2 years ago by @jepcastel
show all tags
Biological
Biological:analysis
BiomedicalResearch
BiomedicalResearch:standards
GeneticMarkers
Genomics
Humans
Neoplasms
Neoplasms:diagnosis
PracticeGuidelinesasTopic
Prognosis
Proteomics
ResearchDesign
TumorMarkers
BiologicalBiological:analysisBiomedicalResearchBiomedicalResearch:standardsGeneticMarkersGenomicsHumansNeoplasmsNeoplasms:diagnosisPracticeGuidelinesasTopicPrognosisProteomicsResearchDesignTumorMarkers
(0)
copydeleteadd this publication to your clipboard
1A guideline for reporting results of statistical analysis in Japanese Journal of Clinical Oncology.
H. Fukuda, and Y. Ohashi. Japanese journal of clinical oncology, 27 (3): 121-7 (June 1997)3204<m:linebreak></m:linebreak>Publicació.
2 years ago by @jepcastel
show all tags
Humans
Japan
ManuscriptsasTopic
MedicalOncology
MultivariateAnalysis
Neoplasms
Neoplasms:mortality
PeriodicalsasTopic
RegressionAnalysis
ResearchDesign
StatisticsasTopic
SurvivalAnalysis
SurvivalRate
HumansJapanManuscriptsasTopicMedicalOncologyMultivariateAnalysisNeoplasmsNeoplasms:mortalityPeriodicalsasTopicRegressionAnalysisResearchDesignStatisticsasTopicSurvivalAnalysisSurvivalRate
(0)
copydeleteadd this publication to your clipboard
1Varieties of uncertainty and the validity of informed consent.
K. Weinfurt. Clinical trials (London, England), 5 (6): 624-5; discussion 630 (January 2008)4680<m:linebreak></m:linebreak>GR: 5R01CA100771-04/CA/NCI NIH HHS/United States; JID: 101197451; ppublish;<m:linebreak></m:linebreak>Data protection.
2 years ago by @jepcastel
show all tags
ClinicalTrials
Disclosure
Humans
InformedConsent
InformedConsent:ethics
InformedConsent:psychology
Neoplasms
Neoplasms:drugtherapy
Neoplasms:psychology
PatientEducationasTopic
PhaseIasTopic
PhaseIasTopic:ethics
PhaseIasTopic:psychology
RiskAssessment
Uncertainty
ClinicalTrialsDisclosureHumansInformedConsentInformedConsent:ethicsInformedConsent:psychologyNeoplasmsNeoplasms:drugtherapyNeoplasms:psychologyPatientEducationasTopicPhaseIasTopicPhaseIasTopic:ethicsPhaseIasTopic:psychologyRiskAssessmentUncertainty
(0)
copydeleteadd this publication to your clipboard
1Sample sizes for constructing confidence intervals and testing hypotheses.
D. Bristol. Statistics in medicine, 8 (7): 803-11 (July 1989)2875<m:linebreak></m:linebreak>Sample size; Límits de confiança.
2 years ago by @jepcastel
show all tags
AnginaPectoris
AnginaPectoris:drugtherapy
AnginaPectoris:physiopathology
ClinicalTrialsasTopic
ClinicalTrialsasTopic:methods
Electrocardiography
Humans
Neoplasms
Neoplasms:drugtherapy
StatisticsasTopic
AnginaPectorisAnginaPectoris:drugtherapyAnginaPectoris:physiopathologyClinicalTrialsasTopicClinicalTrialsasTopic:methodsElectrocardiographyHumansNeoplasmsNeoplasms:drugtherapyStatisticsasTopic
(0)
copydeleteadd this publication to your clipboard
1Competing risk analyses: how are they different and why should you care?
R. Chappell. Clinical cancer research : an official journal of the American Association for Cancer Research, 18 (8): 2127-9 (April 2012)6822<m:linebreak></m:linebreak>CI: (c)2012; JID: 9502500; CON: Clin Cancer Res. 2012 Apr 15;18(8):2301-8. PMID: 22282466; 2012/03/16 aheadofprint; ppublish;<m:linebreak></m:linebreak>Anàlisi de supervivència; Competing risks.
2 years ago by @jepcastel
show all tags
DataInterpretation
Humans
Male
Neoplasms
Neoplasms:therapy
ProportionalHazardsModels
ProstaticNeoplasms
ProstaticNeoplasms:therapy
Statistical
DataInterpretationHumansMaleNeoplasmsNeoplasms:therapyProportionalHazardsModelsProstaticNeoplasmsProstaticNeoplasms:therapyStatistical
(0)
copydeleteadd this publication to your clipboard
1Concepts in cancer survival analysis: research questions, data, and models.
E. Steyerberg, and T. Gerds. Surgical oncology, 19 (2): 52-4; discussion 61 (June 2010)6174<m:linebreak></m:linebreak>LR: 20110602; JID: 9208188; NIHMS190989; OID: NLM: NIHMS190989; OID: NLM: PMC2878891; 2010/02/04 received; 2010/03/11 accepted; 2010/04/08 aheadofprint; ppublish;<m:linebreak></m:linebreak>Anàlisi de supervivència.
2 years ago by @jepcastel
show all tags
BiomedicalResearch
DataInterpretation
Humans
Kaplan-MeierEstimate
Models
Neoplasms
Neoplasms:mortality
ProportionalHazardsModels
RegressionAnalysis
Risk
RiskAssessment
Statistical
SurvivalAnalysis
BiomedicalResearchDataInterpretationHumansKaplan-MeierEstimateModelsNeoplasmsNeoplasms:mortalityProportionalHazardsModelsRegressionAnalysisRiskRiskAssessmentStatisticalSurvivalAnalysis
(0)
copydeleteadd this publication to your clipboard
1Expectations, validity, and reality in gene expression profiling.
K. Kim, S. Zakharkin, and D. Allison. Journal of clinical epidemiology, 63 (9): 950-9 (September 2010)7117<m:linebreak></m:linebreak>LR: 20110913; GR: P01 AG025532-02/AG/NIA NIH HHS/United States; GR: P01 AG025532-03/AG/NIA NIH HHS/United States; GR: P01AG025532/AG/NIA NIH HHS/United States; GR: P30 DK056336-05/DK/NIDDK NIH HHS/United States; GR: P30DK056336/DK/NIDDK NIH HHS/United States; JID: 8801383; 0 (Biological Markers); NIHMS199602; OID: NLM: NIHMS199602; OID: NLM: PMC2910173; 2009/06/11 received; 2010/02/09 revised; 2010/02/11 accepted; 2010/06/25 aheadofprint; ppublish;<m:linebreak></m:linebreak>Epidemiologia genètica.
2 years ago by @jepcastel
show all tags
BiologicalMarkers
ClinicalTrialsasTopic
Databases
GeneExpressionProfiling
GeneExpressionProfiling:instrumentation
GeneExpressionProfiling:methods
Genetic
Genetic:genetics
Humans
InformationStorageandRetrieval
InformationStorageandRetrieval:methods
MicroarrayAnalysis
MicroarrayAnalysis:methods
Neoplasms
Neoplasms:diagnosis
Neoplasms:genetics
ReproducibilityofResults
Transcription
BiologicalMarkersClinicalTrialsasTopicDatabasesGeneExpressionProfilingGeneExpressionProfiling:instrumentationGeneExpressionProfiling:methodsGeneticGenetic:geneticsHumansInformationStorageandRetrievalInformationStorageandRetrieval:methodsMicroarrayAnalysisMicroarrayAnalysis:methodsNeoplasmsNeoplasms:diagnosisNeoplasms:geneticsReproducibilityofResultsTranscription
(0)
copydeleteadd this publication to your clipboard
1Clinical and outcome research in oncology. The need for integration.
G. Apolone. Health and quality of life outcomes, (January 2003)5220<m:linebreak></m:linebreak>JID: 101153626; 0 (Antineoplastic Agents); OID: NLM: PMC155672; 2003/02/27 received; 2003/04/03 accepted; 2003/04/03 aheadofprint; epublish;<m:linebreak></m:linebreak>Mesures de resultats.
2 years ago by @jepcastel
show all tags
AntineoplasticAgents
AntineoplasticAgents:therapeuticuse
BiomedicalResearch
BiomedicalResearch:methods
ClinicalTrialsasTopic
DrugApproval
Europe
Humans
MedicalOncology
Neoplasms
Neoplasms:drugtherapy
OutcomeAssessment(HealthCare)
OutcomeAssessment(HealthCare):methods
QualityofLife
UnitedStates
UnitedStatesFoodandDrugAdministration
AntineoplasticAgentsAntineoplasticAgents:therapeuticuseBiomedicalResearchBiomedicalResearch:methodsClinicalTrialsasTopicDrugApprovalEuropeHumansMedicalOncologyNeoplasmsNeoplasms:drugtherapyOutcomeAssessment(HealthCare)OutcomeAssessment(HealthCare):methodsQualityofLifeUnitedStatesUnitedStatesFoodandDrugAdministration
(0)
copydeleteadd this publication to your clipboard
1Methods for pooling results of epidemiologic studies: the Pooling Project of Prospective Studies of Diet and Cancer.
S. Smith-Warner, D. Spiegelman, J. Ritz, D. Albanes, W. Beeson, L. Bernstein, F. Berrino, P. van den Brandt, J. Buring, E. Cho and 22 other author(s). American journal of epidemiology, 163 (11): 1053-64 (June 2006)4809<m:linebreak></m:linebreak>LR: 20071115; GR: CA55075/CA/NCI NIH HHS/United States; GR: CA78548/CA/NCI NIH HHS/United States; JID: 7910653; 2006/04/19 aheadofprint; ppublish;<m:linebreak></m:linebreak>Metaanàlisi.
2 years ago by @jepcastel
show all tags
Diet
EpidemiologicMethods
Humans
Neoplasms
Neoplasms:epidemiology
ProspectiveStudies
RiskFactors
StatisticsasTopic
DietEpidemiologicMethodsHumansNeoplasmsNeoplasms:epidemiologyProspectiveStudiesRiskFactorsStatisticsasTopic
(0)
copydeleteadd this publication to your clipboard
1Immortal person-time in studies of cancer outcomes.
T. Lash, and S. Cole. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 (23): e55-6 (August 2009)5436<m:linebreak></m:linebreak>JID: 8309333; 2009/07/13 aheadofprint; ppublish;<m:linebreak></m:linebreak>Mesures d'associació; Immortal time bias.
2 years ago by @jepcastel
show all tags
DataInterpretation
Humans
Neoplasms
Neoplasms:mortality
Neoplasms:therapy
ProspectiveStudies
ResearchDesign
RetrospectiveStudies
Statistical
SurvivalAnalysis
SurvivalRate
TimeFactors
TreatmentOutcome
DataInterpretationHumansNeoplasmsNeoplasms:mortalityNeoplasms:therapyProspectiveStudiesResearchDesignRetrospectiveStudiesStatisticalSurvivalAnalysisSurvivalRateTimeFactorsTreatmentOutcome
(0)
copydeleteadd this publication to your clipboard
1Definition, sources, magnitude, effect modifiers, and strategies of reduction of the healthy worker effect.
B. Choi. Journal of occupational medicine. : official publication of the Industrial Medical Association, 34 (10): 979-88 (October 1992)2685<m:linebreak></m:linebreak>Mesures d'associació.
2 years ago by @jepcastel
show all tags
AgeFactors
Bias(Epidemiology)
CauseofDeath
ConfoundingFactors(Epidemiology)
Diagnosis
Differential
EffectModifier
Employment
Epidemiologic
HealthyWorkerEffect
Humans
Neoplasms
Neoplasms:epidemiology
OccupationalDiseases
OccupationalDiseases:epidemiology
OccupationalDiseases:mortality
OccupationalHealth
Occupations
Population
ResearchDesign
RiskFactors
SexFactors
SocialClass
SocialConditions
AgeFactorsBias(Epidemiology)CauseofDeathConfoundingFactors(Epidemiology)DiagnosisDifferentialEffectModifierEmploymentEpidemiologicHealthyWorkerEffectHumansNeoplasmsNeoplasms:epidemiologyOccupationalDiseasesOccupationalDiseases:epidemiologyOccupationalDiseases:mortalityOccupationalHealthOccupationsPopulationResearchDesignRiskFactorsSexFactorsSocialClassSocialConditions
(0)
copydeleteadd this publication to your clipboard
1A predictive probability design for phase II cancer clinical trials.
J. Lee, and D. Liu. Clinical trials (London, England), 5 (2): 93-106 (January 2008)5653<m:linebreak></m:linebreak>GR: CA97007/CA/NCI NIH HHS/United States; JID: 101197451; 0 (Antineoplastic Agents); ppublish;<m:linebreak></m:linebreak>Fase II.
2 years ago by @jepcastel
show all tags
AntineoplasticAgents
AntineoplasticAgents:therapeuticuse
BayesTheorem
Bias(Epidemiology)
ClinicalTrials
DataInterpretation
Humans
Neoplasms
Neoplasms:drugtherapy
PhaseIIasTopic
PhaseIIasTopic:methods
PhaseIIasTopic:statistics&numericaldata
Probability
ResearchDesign
Statistical
AntineoplasticAgentsAntineoplasticAgents:therapeuticuseBayesTheoremBias(Epidemiology)ClinicalTrialsDataInterpretationHumansNeoplasmsNeoplasms:drugtherapyPhaseIIasTopicPhaseIIasTopic:methodsPhaseIIasTopic:statistics&numericaldataProbabilityResearchDesignStatistical
(0)
copydeleteadd this publication to your clipboard

⟨⟨
⟨
1
2
3
⟩
⟩⟩

BibSonomy

bookmarks (hide)
display
all
bookmarks only
bookmarks per page
5
10
20
50
100
sort by
added at
title
RSS
BibTeX
XML

publications (hide)124
display
all
publications only
publications per page
5
10
20
50
100
sort by
added at
title
author
publication date
entry type
help for advanced sorting...
RSS
BibTeX
RDF
more...

1Precision of incidence predictions based on Poisson distributed observations.

1An electronic application for rapidly calculating Charlson comorbidity score.

1Mortality from tobacco in developed countries: indirect estimation from national vital statistics.

1A unified approach to the analysis of case-distribution (case-only) studies.

1On the measurement of susceptibility in epidemiologic studies.

1The statistics of phase 0 trials.

1Progression-free survival remains debatable endpoint in cancer trials.

1Evolution of cancer survival analysis.

1How to improve reliability and efficiency of research about molecular markers: roles of phases, guidelines, and study design.

1A guideline for reporting results of statistical analysis in Japanese Journal of Clinical Oncology.

1Varieties of uncertainty and the validity of informed consent.

1Sample sizes for constructing confidence intervals and testing hypotheses.

1Competing risk analyses: how are they different and why should you care?

1Concepts in cancer survival analysis: research questions, data, and models.

1Expectations, validity, and reality in gene expression profiling.

1Clinical and outcome research in oncology. The need for integration.

1Methods for pooling results of epidemiologic studies: the Pooling Project of Prospective Studies of Diet and Cancer.

1Immortal person-time in studies of cancer outcomes.

1Definition, sources, magnitude, effect modifiers, and strategies of reduction of the healthy worker effect.

1A predictive probability design for phase II cancer clinical trials.

browse

related tags

bookmarks (hide) displayallbookmarks onlybookmarks per page5102050100 sort byadded attitle RSSBibTeXXML

publications (hide)124 displayallpublications onlypublications per page5102050100 sort byadded attitleauthorpublication dateentry typehelp for advanced sorting... RSSBibTeXRDFmore...

browse

related tags

bookmarks (hide)
display
all
bookmarks only
bookmarks per page
5
10
20
50
100
sort by
added at
title
RSS
BibTeX
XML

publications (hide)124
display
all
publications only
publications per page
5
10
20
50
100
sort by
added at
title
author
publication date
entry type
help for advanced sorting...
RSS
BibTeX
RDF
more...